Welcome to our dedicated page for Standex Intl SEC filings (Ticker: SXI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Standex International Corporation (NYSE: SXI) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into Standex’s financial performance, governance practices, executive compensation, and shareholder matters.
Standex submits a variety of forms, including Form 8-K current reports and its DEF 14A definitive proxy statement. Recent Form 8-K filings have covered topics such as the announcement of quarterly earnings, the results of the Annual Meeting of Shareholders, and changes in executive roles. Through these reports, investors can review information on segment performance across Electronics, Engineering Technologies, Scientific, Engraving, and Specialty Solutions, as well as commentary on revenue, margins, and capital allocation.
The company’s definitive proxy statement describes board leadership structure, board committees, strategy and risk oversight, ESG strategy and risks, director compensation, director independence, and stock ownership. It also details the items presented to shareholders for voting, including director elections, advisory votes on executive compensation, and ratification of the independent auditors.
On this page, filings are updated as they are made available on EDGAR. AI-powered tools summarize key points from lengthy documents, helping users quickly identify topics such as shareholder vote outcomes, executive compensation disclosures, and significant corporate events reported on Form 8-K. Investors can use these summaries alongside the full-text filings to better understand Standex’s regulatory reporting and governance framework.
Standex International director Barbara Joanne Edwards reported a charitable-type move involving company stock. On February 23, 2026, she transferred 58 shares of Standex International common stock as a bona fide gift with no consideration received. After this gift transfer, she directly owned 6,227 common shares of Standex International.
Standex International director Charles H. Cannon Jr. reported an open-market sale of 2,000 shares of common stock at $256.64 per share. The shares were held indirectly as Trustee of a Trust, which reported 13,046 shares remaining after the sale. Separately, Cannon reported 2,280 shares of common stock held directly, with this line reflecting a reported holding rather than a new transaction.
STANDEX INTERNATIONAL CORP/DE/ Chief Strategy Officer Kshirsagar Vineet sold 400 shares of common stock in an open-market transaction. The sale occurred on February 18, 2026, at a price of $260.10 per share. After this transaction, he directly owns 4,647 shares.
Standex International’s President, CEO, and Chairman David A. Dunbar reported indirect open-market sales of company common stock under a pre-arranged Rule 10b5-1 trading plan dated November 12, 2025. On February 17, 2026, a trust for which he serves as trustee sold 10,000 shares at a weighted average price of $255.98 per share and 5,000 shares at a weighted average price of $255.87 per share. Following these planned sales, indirect holdings held as trustee totaled 88,973 shares, and direct ownership stood at 1,429.9759 shares.
Fidelity Brokerage Services LLC reported a proposed sale of 400 common shares of SXI with an aggregate amount listed as $104,040.00 and an indicated market of NYSE on 02/18/2026. The record lists prior issuances of 383 shares from restricted stock vesting on 09/06/2021 and 17 shares from an ESPP purchase on 09/30/2021.
Standex International Corporation insider filed a notice of proposed stock sales under Rule 144. The filing covers up to 15,000 shares of common stock to be sold through UBS Financial Services on or around 02/17/2026, with an aggregate market value of $3,912,150.00.
The shares relate to restricted stock units that vested on 08/23/2024, when 15,000 common shares were acquired from the issuer. The filing notes that 12,118,733 common shares were outstanding, providing context for the size of the planned sale relative to the company’s equity base.
Champlain Investment Partners, LLC reported beneficial ownership of 488,359 shares of Standex International common stock, representing 4.0% of the class as of September 30, 2025. Champlain has sole voting power over 308,124 shares and sole dispositive power over all 488,359 shares.
The firm certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Standex International, nor in connection with any transaction aimed at that purpose.
A shareholder of SXI has filed a notice of intent to sell 2,000 shares of common stock through The Charles Schwab Corporation on the NYSE. The shares have an indicated aggregate market value of $519,640.00, with the sale expected around February 9, 2026.
The filing shows these shares were acquired via restricted stock awards from the issuer as equity compensation on October 28, 2011 and October 25, 2025. The shareholder also represents that they are not aware of undisclosed material adverse information about the company’s operations.
Standex International Corporation director Thomas E. Chorman reported a small planned sale of company stock. On February 4, 2026, he sold 50 shares of common stock at a price of $249.86 per share under an existing Rule 10b5-1 trading plan dated November 6, 2025.
After this transaction, Chorman beneficially owned 13,179 shares of Standex common stock, held directly in his name.
Standex International Corporation filed a current report to furnish its second-quarter earnings news. The company states that it issued a press release announcing financial results for the quarter ended December 31, 2025, and has attached this release as an exhibit.
The press release, dated January 29, 2026, is provided as Exhibit 99 and is incorporated by reference. The filing is made under Item 2.02, which covers results of operations and financial condition, and includes standard cautionary language about forward-looking statements and related risk factors.